TW200408401A - Chinese herbal medicine composition capable of improving memory acquisition (learning) capability - Google Patents
Chinese herbal medicine composition capable of improving memory acquisition (learning) capability Download PDFInfo
- Publication number
- TW200408401A TW200408401A TW91134626A TW91134626A TW200408401A TW 200408401 A TW200408401 A TW 200408401A TW 91134626 A TW91134626 A TW 91134626A TW 91134626 A TW91134626 A TW 91134626A TW 200408401 A TW200408401 A TW 200408401A
- Authority
- TW
- Taiwan
- Prior art keywords
- chinese medicine
- medicine composition
- traditional chinese
- scope
- patent application
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 241000411851 herbal medicine Species 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241000157352 Uncaria Species 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 12
- 241000305492 Gastrodia Species 0.000 claims description 10
- 240000000249 Morus alba Species 0.000 claims description 9
- 235000008708 Morus alba Nutrition 0.000 claims description 9
- 244000045947 parasite Species 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000008298 dragée Substances 0.000 claims description 5
- 230000035622 drinking Effects 0.000 claims description 5
- 235000021271 drinking Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 235000015961 tonic Nutrition 0.000 claims description 5
- 230000001256 tonic effect Effects 0.000 claims description 5
- 229960000716 tonics Drugs 0.000 claims description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- 241000427159 Achyranthes Species 0.000 claims description 3
- 241000207925 Leonurus Species 0.000 claims description 3
- 241000282537 Mandrillus sphinx Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 2
- 241000208689 Eucommia ulmoides Species 0.000 claims 2
- 230000024241 parasitism Effects 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 244000237330 gutta percha tree Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 240000000031 Achyranthes bidentata Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- 101100467407 Rattus norvegicus Rab3il1 gene Proteins 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000023406 head swelling Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW91134626A TW200408401A (en) | 2002-11-28 | 2002-11-28 | Chinese herbal medicine composition capable of improving memory acquisition (learning) capability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW91134626A TW200408401A (en) | 2002-11-28 | 2002-11-28 | Chinese herbal medicine composition capable of improving memory acquisition (learning) capability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200408401A true TW200408401A (en) | 2004-06-01 |
| TWI313607B TWI313607B (enrdf_load_stackoverflow) | 2009-08-21 |
Family
ID=45072802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW91134626A TW200408401A (en) | 2002-11-28 | 2002-11-28 | Chinese herbal medicine composition capable of improving memory acquisition (learning) capability |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200408401A (enrdf_load_stackoverflow) |
-
2002
- 2002-11-28 TW TW91134626A patent/TW200408401A/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI313607B (enrdf_load_stackoverflow) | 2009-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ridtitid et al. | Antinociceptive activity of the methanolic extract of Kaempferia galanga Linn. in experimental animals | |
| US20130123212A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN101652143B (zh) | 用于选择性5-羟色胺再摄取抑制的组合物及其方法 | |
| CN101804127B (zh) | 一种防治老年痴呆症的复方中药提取物组合物 | |
| CN103169737A (zh) | 樟芝子实体与破壁灵芝孢子粉的组合物及其在免疫调节中的应用 | |
| CN101797267B (zh) | 一种防治老年痴呆症的药物组合物 | |
| CN109289009A (zh) | 一种中药组合物及其制备方法和应用 | |
| CN102274268B (zh) | 一种具有戒酒作用的中药活性提取物、其制备方法和应用 | |
| KR101990758B1 (ko) | 노인성 치매의 예방과 치료에 사용되는 의약 조성물 및 그 제조 방법 | |
| TW200408401A (en) | Chinese herbal medicine composition capable of improving memory acquisition (learning) capability | |
| JP2008521839A (ja) | 大葉（叶）蒟抽出物の調製方法、抽出物及びその応用 | |
| Ijioma et al. | Antimotility effect of a southeast Nigerian polyherbal combination (Ajumbise): An in-vitro and in-vivo evaluation | |
| TW201841903A (zh) | 末梢神經障礙之治療劑或預防劑 | |
| CN104095938B (zh) | 一种治疗抑郁症的蒙药制剂 | |
| CN103908567B (zh) | 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用 | |
| Chung et al. | Effects of Elsholtzia splendens and Cirsium japonicum on premenstrual syndrome | |
| CN100389780C (zh) | 一种抗抑郁症的中药及其制备方法 | |
| CN101966193B (zh) | 2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷在制备治疗抑郁症药物中的应用 | |
| CN119633016B (zh) | 天麻活性成分在制备治疗阿尔兹海默症药物中的应用 | |
| TWI404542B (zh) | 用於治療抽動症及具有感覺運動門控不良之精神疾病的海州常山屬組合物 | |
| CN101450063A (zh) | 治疗忧郁症的口服药物 | |
| KR101828102B1 (ko) | 토후박 추출물을 함유하는 구토 또는 설사의 치료용 조성물 | |
| KR101695052B1 (ko) | 나복자 추출물을 포함하는 구토 또는 설사의 치료용 조성물 | |
| US9358265B2 (en) | Plant based formulation for the prevention and management of irritable bowel syndrome (IBS) | |
| Owolabi et al. | Effect of aqueous extract of Persea americana Mill (Lauraceae) seeds on non-pregnant rat uterus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |